View in EDS

Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach.

Saved in:
Bibliographic Details
Title: Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach.
Authors: Terstiege I; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.. Electronic address: Ina.Terstiege@astrazeneca.com., Aagaard A; Protein Science, Structural Biology & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Berggren K; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Bird J; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Cumming IA; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Groombridge SD; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hidestål L; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Johannesson P; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Korsgren P; Compound Synthesis and Management, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Leuchowius KJ; Assays, Profiling and Cell Sciences, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Lundqvist S; Assays, Profiling and Cell Sciences, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Scott JS; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Xue Y; Protein Science, Structural Biology & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Degorce SL; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Source: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2025 Dec 15; Vol. 131, pp. 118333. Date of Electronic Publication: 2025 Jul 28.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: England NLM ID: 9413298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3391 (Electronic) Linking ISSN: 09680896 NLM ISO Abbreviation: Bioorg Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40972347
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Terstiege+I%22">Terstiege I</searchLink>; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.. Electronic address: Ina.Terstiege@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Aagaard+A%22">Aagaard A</searchLink>; Protein Science, Structural Biology & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Berggren+K%22">Berggren K</searchLink>; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Bird+J%22">Bird J</searchLink>; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Cumming+IA%22">Cumming IA</searchLink>; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Groombridge+SD%22">Groombridge SD</searchLink>; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hidestål+L%22">Hidestål L</searchLink>; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Johannesson+P%22">Johannesson P</searchLink>; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Korsgren+P%22">Korsgren P</searchLink>; Compound Synthesis and Management, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Leuchowius+KJ%22">Leuchowius KJ</searchLink>; Assays, Profiling and Cell Sciences, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Lundqvist+S%22">Lundqvist S</searchLink>; Assays, Profiling and Cell Sciences, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Scott+JS%22">Scott JS</searchLink>; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Xue+Y%22">Xue Y</searchLink>; Protein Science, Structural Biology & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Degorce+SL%22">Degorce SL</searchLink>; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229413298%22">Bioorganic & medicinal chemistry</searchLink> [Bioorg Med Chem] 2025 Dec 15; Vol. 131, pp. 118333. <i>Date of Electronic Publication: </i>2025 Jul 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9413298 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1464-3391 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209680896%22">09680896 </searchLink><i>NLM ISO Abbreviation: </i>Bioorg Med Chem <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40972347
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.bmc.2025.118333
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 118333
    Titles:
      – TitleFull: Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Terstiege I
      – PersonEntity:
          Name:
            NameFull: Aagaard A
      – PersonEntity:
          Name:
            NameFull: Berggren K
      – PersonEntity:
          Name:
            NameFull: Bird J
      – PersonEntity:
          Name:
            NameFull: Cumming IA
      – PersonEntity:
          Name:
            NameFull: Groombridge SD
      – PersonEntity:
          Name:
            NameFull: Hidestål L
      – PersonEntity:
          Name:
            NameFull: Johannesson P
      – PersonEntity:
          Name:
            NameFull: Korsgren P
      – PersonEntity:
          Name:
            NameFull: Leuchowius KJ
      – PersonEntity:
          Name:
            NameFull: Lundqvist S
      – PersonEntity:
          Name:
            NameFull: Scott JS
      – PersonEntity:
          Name:
            NameFull: Xue Y
      – PersonEntity:
          Name:
            NameFull: Degorce SL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 12
              Text: 2025 Dec 15
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1464-3391
          Numbering:
            – Type: volume
              Value: 131
          Titles:
            – TitleFull: Bioorganic & medicinal chemistry
              Type: main
ResultId 1